[
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Pfizer Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $24.15 as of September 18th. PFE’s trailing and forward P/E were 12.78 and 7.74 respectively according to Yahoo Finance. Pfizer (PFE) has experienced a sharp post-COVID […]",
    "url": "https://finnhub.io/api/news?id=b78ec51e9e6da7024049f934cf6e6167fd372faff2c35ec04cd9ebc50403e4ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759090992,
      "headline": "Pfizer Inc. (PFE): A Bull Case Theory",
      "id": 136913723,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Pfizer Inc. on Investing With Purpose’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $24.15 as of September 18th. PFE’s trailing and forward P/E were 12.78 and 7.74 respectively according to Yahoo Finance. Pfizer (PFE) has experienced a sharp post-COVID […]",
      "url": "https://finnhub.io/api/news?id=b78ec51e9e6da7024049f934cf6e6167fd372faff2c35ec04cd9ebc50403e4ad"
    }
  },
  {
    "ts": null,
    "headline": "Inside MrBeast's $5 Billion Generosity Machine — and the Hidden Costs Behind It",
    "summary": "Internet sensation Jimmy Donaldson, better known as MrBeast, has successfully established an entertainment empire valued at over $5 billion. His unique approach combines YouTube popularity with large-scale philanthropy. His company, Beast Industries, has been recognized in Fortune’s 2025 Change the World list. Donaldson’s journey to stardom started with YouTube videos featuring charitable acts. Today, he is one of the biggest internet celebrities with 435 million subscribers and over 95 billion",
    "url": "https://finnhub.io/api/news?id=9f23ded7a60c8a80f77b06fb94c71d3c174236872e3659483bc2d4125f8ce009",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759086698,
      "headline": "Inside MrBeast's $5 Billion Generosity Machine — and the Hidden Costs Behind It",
      "id": 136913724,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Internet sensation Jimmy Donaldson, better known as MrBeast, has successfully established an entertainment empire valued at over $5 billion. His unique approach combines YouTube popularity with large-scale philanthropy. His company, Beast Industries, has been recognized in Fortune’s 2025 Change the World list. Donaldson’s journey to stardom started with YouTube videos featuring charitable acts. Today, he is one of the biggest internet celebrities with 435 million subscribers and over 95 billion",
      "url": "https://finnhub.io/api/news?id=9f23ded7a60c8a80f77b06fb94c71d3c174236872e3659483bc2d4125f8ce009"
    }
  },
  {
    "ts": null,
    "headline": "Why Pfizer's Post-COVID Future Looks Brighter Than Ever",
    "summary": "A robust pipeline of experimental and recently launched drugs could make the next several years exciting ones to be a Pfizer shareholder.",
    "url": "https://finnhub.io/api/news?id=831f678577e876cb1e759106a04ac49cfa8d29e91ffaf343fc0dc16aac97227d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759080480,
      "headline": "Why Pfizer's Post-COVID Future Looks Brighter Than Ever",
      "id": 136913725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A robust pipeline of experimental and recently launched drugs could make the next several years exciting ones to be a Pfizer shareholder.",
      "url": "https://finnhub.io/api/news?id=831f678577e876cb1e759106a04ac49cfa8d29e91ffaf343fc0dc16aac97227d"
    }
  },
  {
    "ts": null,
    "headline": "BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival",
    "summary": "BridgeBio Pharma said Sunday its heart-disease drug, Attruby, cut the risk of death almost in half in an exploratory study.",
    "url": "https://finnhub.io/api/news?id=a8afbdfc75cb4c45ca51bfeaa9bcc1b96a7ac7373ba922db4c719bc554726432",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759072558,
      "headline": "BridgeBio, Up 80% This Year, Just Unveiled Promising News For Its Pfizer Rival",
      "id": 136907549,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "BridgeBio Pharma said Sunday its heart-disease drug, Attruby, cut the risk of death almost in half in an exploratory study.",
      "url": "https://finnhub.io/api/news?id=a8afbdfc75cb4c45ca51bfeaa9bcc1b96a7ac7373ba922db4c719bc554726432"
    }
  },
  {
    "ts": null,
    "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
    "summary": "Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track.",
    "url": "https://finnhub.io/api/news?id=28352956f26e320e976bcfa09d9ad5e4207a057f549a17eb615efc3931a20787",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759071480,
      "headline": "Down 55%, Should You Buy the Dip on Pfizer?",
      "id": 136907550,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer is facing a patent cliff and has a high payout ratio, but it is taking steps to get back on track.",
      "url": "https://finnhub.io/api/news?id=28352956f26e320e976bcfa09d9ad5e4207a057f549a17eb615efc3931a20787"
    }
  },
  {
    "ts": null,
    "headline": "5 Dividend Powerhouses to Buy and Never Sell",
    "summary": "These blue-chip giants have paid shareholders through wars, recessions, and pandemics.",
    "url": "https://finnhub.io/api/news?id=f13cbf9084544adeb21cd3f5a98839d1e2ace7d7233c57363d6f1cbd40b99394",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759068000,
      "headline": "5 Dividend Powerhouses to Buy and Never Sell",
      "id": 136907491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These blue-chip giants have paid shareholders through wars, recessions, and pandemics.",
      "url": "https://finnhub.io/api/news?id=f13cbf9084544adeb21cd3f5a98839d1e2ace7d7233c57363d6f1cbd40b99394"
    }
  },
  {
    "ts": null,
    "headline": "Declining Stock and Decent Financials: Is The Market Wrong About Pfizer Inc. (NYSE:PFE)?",
    "summary": "Pfizer (NYSE:PFE) has had a rough month with its share price down 4.0%. But if you pay close attention, you might find...",
    "url": "https://finnhub.io/api/news?id=e87ea8270f0563ae8ef2be6ea8e4149ea3874ead43e7bff3ece4d8cccfa5f963",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759060833,
      "headline": "Declining Stock and Decent Financials: Is The Market Wrong About Pfizer Inc. (NYSE:PFE)?",
      "id": 136907552,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (NYSE:PFE) has had a rough month with its share price down 4.0%. But if you pay close attention, you might find...",
      "url": "https://finnhub.io/api/news?id=e87ea8270f0563ae8ef2be6ea8e4149ea3874ead43e7bff3ece4d8cccfa5f963"
    }
  },
  {
    "ts": null,
    "headline": "Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs",
    "summary": "Discover 2024's top Barron's Better Bets dividend stocks poised for 23.96% average gains. See which picks offer strong income & outperformance.",
    "url": "https://finnhub.io/api/news?id=ddd46ff2d850c3ba4b011f8a4ed69c6d8522280ce4b45d1281723e9ccffb3fa5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759054205,
      "headline": "Buy 7 Barron's Better Bets (Than T-Bills) From 15 'Safer' Of 23 September Dividend Dogs",
      "id": 136906962,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522637014/image_522637014.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover 2024's top Barron's Better Bets dividend stocks poised for 23.96% average gains. See which picks offer strong income & outperformance.",
      "url": "https://finnhub.io/api/news?id=ddd46ff2d850c3ba4b011f8a4ed69c6d8522280ce4b45d1281723e9ccffb3fa5"
    }
  },
  {
    "ts": null,
    "headline": "A Generational Opportunity To Buy Dividends At Fire-Sale Prices",
    "summary": "Discover top dividend stocks trading at discounts and set for a rebound.",
    "url": "https://finnhub.io/api/news?id=e4ebf39e9ce0272d44f553a737c0eaa524942d2d40ddec22cd7d9ecebc22d54d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759050300,
      "headline": "A Generational Opportunity To Buy Dividends At Fire-Sale Prices",
      "id": 136906728,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1289941019/image_1289941019.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover top dividend stocks trading at discounts and set for a rebound.",
      "url": "https://finnhub.io/api/news?id=e4ebf39e9ce0272d44f553a737c0eaa524942d2d40ddec22cd7d9ecebc22d54d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's Bold GLP‑1 Comeback, Dividend Safe For Now",
    "summary": "Pfizer acquires Metsera to enter the booming obesity drug market with next-gen GLP-1 therapies. Find out why PFE stock is a hold.",
    "url": "https://finnhub.io/api/news?id=eb1a03a9afdaa0d5ecccf5745dcdfb5f6c13a3da36e40decc43d09225954d1f8",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759039378,
      "headline": "Pfizer's Bold GLP‑1 Comeback, Dividend Safe For Now",
      "id": 136906174,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer acquires Metsera to enter the booming obesity drug market with next-gen GLP-1 therapies. Find out why PFE stock is a hold.",
      "url": "https://finnhub.io/api/news?id=eb1a03a9afdaa0d5ecccf5745dcdfb5f6c13a3da36e40decc43d09225954d1f8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: A Reluctant Upgrade To Hold",
    "summary": "Pfizerâs Metsera acquisition boosts its obesity/GLP-1 pipeline and revenue outlook. See why I'm cautiously upgrading my rating on PFE stock to a Hold.",
    "url": "https://finnhub.io/api/news?id=b818eb22a2a3d9af0ddf986facc2f5d41e25617fe556073c57149aaa787f3bbb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759032492,
      "headline": "Pfizer: A Reluctant Upgrade To Hold",
      "id": 136905725,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2127947112/image_2127947112.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizerâs Metsera acquisition boosts its obesity/GLP-1 pipeline and revenue outlook. See why I'm cautiously upgrading my rating on PFE stock to a Hold.",
      "url": "https://finnhub.io/api/news?id=b818eb22a2a3d9af0ddf986facc2f5d41e25617fe556073c57149aaa787f3bbb"
    }
  }
]